Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (49)	4/1/2002 9:30:40 AM
From: tuck	Respond to of 510

LumiCyte, which doesn't seem to have any poster presentations at AACR, is instead hyping its booth: >>(BW HealthWire)-- LumiCyte Will Display Their Revolutionary SELDI-Based Biotechnology Services at Booth #714 at the AACR 93rd Annual Meeting in San Francisco on April 7-10 WHO LumiCyte, Inc. -- a biotechnology company that enables the early diagnosis of cancer and drives the evolution of drug development. Dr. Bill Hutchens -- Founder and CEO of LumiCyte and inventor of the SELDI proteomics technology. WHAT As an exhibitor at the AACR 93rd Annual Meeting, at the Moscone Convention Center in San Francisco, Calif., LumiCyte will showcase its SELDI-based biotechnology services and announce that it has achieved an exciting new level of protein-mapping capabilities as benchmarked by today's most sophisticated technologies. LumiCyte generates high-information content protein maps with unprecedented speed, sensitivity and accuracy. Analysis of these maps with LumiCyte's proprietary suite of neural network and pattern recognition software enables: -- Early detection of disease onset -- More effective classification of disease -- More accurate monitoring of disease progression -- Early indication of patient-specific response to therapy LumiCyte's biochip products are low cost, distributable sample collection and diagnostic devices that are being used in support of clinical trials. WHEN: April 7-10, 2002 WHERE: Moscone Convention Center, Booth 714, San Francisco, Calif. INTERVIEWS: Dr. Bill Hutchens will be available on April 8-10 by appointment only. Hutchens and the team at LumiCyte pioneered the development of advanced biochips and informatics technologies to generate comprehensive human serum protein maps. To schedule a meeting, contact either: CONTACT: J.P. Carr Louise Bono Sterling Hager LumiCyte, Inc. 415/591-8402 510/413-9224 jp@sterlinghager.com lbono@lumicyte.com LumiCyte: The advanced, proprietary biotechnology services offered exclusively by Fremont, Calif.-based LumiCyte, Inc. allow pharmaceutical and biotechnology companies to optimize drug development, and enable physicians to offer more individualized and accurate care to their patients. www.lumicyte.com LumiCyte combines THREE core technologies to offer contract services that remove the inefficiencies found today in the pharmaceutical and biotechnology industries' multi-billion dollar drug development process: 1. Advanced SELDI Biochips that feature the most sensitive, accurate and comprehensive protein-mapping capabilities available. 2. Patented and proprietary Data Analysis Software that was developed to identify patterns within the high-resolution protein topographical maps produced by the LumiCyte Biochip. 3. The BioPhore Knowledgebase(TM), an open-architecture information platform that integrates our disease-specific protein information with other genomics, proteomics and clinical information. The BioPhore Knowledgebase currently holds records for over 2200 human serum proteins with 180 descriptors each.<< Cheers, Tuck